facebook
eISSN: 2084-9893
ISSN: 0033-2526
Dermatology Review/Przegląd Dermatologiczny
Bieżący numer Archiwum Artykuły zaakceptowane O czasopiśmie Zeszyty specjalne Rada naukowa Bazy indeksacyjne Prenumerata Kontakt Zasady publikacji prac Standardy etyczne i procedury
Panel Redakcyjny
Zgłaszanie i recenzowanie prac online
SCImago Journal & Country Rank
Poleć ten artykuł:
Udostępnij:
streszczenie artykułu:

Use of rituximab in the treatment of pemphigus vulgaris in a juvenile patient

Hanna Hanna Cisoń
,
Rafał Białynicki-Birula
,
Wojciech Baran

Data publikacji online: 2024/02/26
Pełna treść artykułu Pobierz cytowanie
 
Metryki PlumX:
Introduction: Pemphigus vulgaris is a chronic autoimmune blistering

disorder characterised by the production of autoantibodies against

desmogleins, resulting in intraepithelial blister formation. Despite

advancements in treatment options, some patients experience disease

progression and an inadequate response to conventional therapies. Rituximab,

a monoclonal chimeric antibody targeting CD20 on B-cells,

has shown promise as an alternative therapeutic option.

Case report: In this case report, we present the management of a

14-year-old child with pemphigus vulgaris who exhibited disease progression

despite conventional treatment modalities. The patient was

administered rituximab therapy, resulting in significant clinical improvement

and disease control.

Conclusions: The utilisation of rituximab as an adjunct or alternative

therapy in refractory pemphigus cases offers a valuable treatment

option. Further studies and long-term follow-up are necessary to determine

the optimal dosing regimen and evaluate the safety and efficacy

of rituximab in paediatric pemphigus patients.
słowa kluczowe:

pemphigus, drug therapy, complications, rituximab, administration and dosage, adverse effects



© 2024 Termedia Sp. z o.o.
Developed by Bentus.